[Levels of monokines in peripheral monocytes in patients with superficial tumors of the bladder treated with BCG. Results after 1- and 3-year follow-up].
BCG has been shown in prospective randomized clinical trials to provide superior therapeutic results when composed to transurethral resection alone, or to adjuvant therapy with Thiotepa or Adriamicin. Even if the mechanism by which BCG mediate antitumor activity are not clearly established, an association between the immunological response and antitumoral activity is known IL-1 and TNF alfa are the monokines that have multiple biological effects, including linfocyte proliferation, production of fever, augmentation of cytotoxicity and production of cytokines. The goal of this study is show the response from LPS induced and not peripheral monocytes of superficial bladder cancer patients BCG treated and not, i.e. the levels of TNF alfa, IL-1 and not IL-6.
Iantorno
R
R
Clinica Urologica, Università degli Studi G. D'annunzio, Chieti.
Nicolai
M
M
Menna
C
C
Tenaglia
R
R
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D001500:BCG Vaccine / Q000627:therapeutic use*; D005500:Follow-Up Studies; D009000:Monocytes / Q000737:chemistry*; D015846:Monokines / Q000032:analysis*; D013997:Time Factors; D001749:Urinary Bladder Neoplasms / Q000276:immunology / Q000628:therapy*
D000276:Adjuvants, Immunologic; D001500:BCG Vaccine; D015846:Monokines